Evidence map›Paper›PMID 26817487›Full record

ArticleThe Journal of antimicrobial chemotherapy2016

Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy.

Marcus J Pond, Catherine L Hall, Victoria F Miari, Michelle Cole, Ken G Laing, Heena Jagatia, Emma Harding-Esch, Irene M Monahan, Timothy Planche, Jason Hinds and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 45 citations in OpenAlex.

  1. Sequence analyses to accelerate the development of rapid resistance assays targeting the Neisseria gonorrhoeae gyrA gene.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Detection ofAntibiotics (Basel, Switzerland) · 2024
    Article
  4. Maximizing theJournal of clinical microbiology · 2024
    Article
  5. Article
  6. Extra-genitalInternational journal of STD & AIDS · 2023
    Article
  7. Article
  8. Current and Future Trends in the Laboratory Diagnosis of Sexually Transmitted Infections.International journal of environmental research and public health · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. The Laboratory Diagnosis ofPathogens (Basel, Switzerland) · 2020
    Review
  13. Article
  14. Review
  15. Culture-free genotyping ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Marcus J PondInstitute for Infection and Immunity, St George's, University of London, London, UK.
Catherine L HallInstitute for Infection and Immunity, St George's, University of London, London, UK.
Victoria F MiariInstitute for Infection and Immunity, St George's, University of London, London, UK.
Michelle ColeSexually Transmitted Bacteria Reference Unit, Public Health England, Colindale, London, UK.
Ken G LaingInstitute for Infection and Immunity, St George's, University of London, London, UK.
Heena JagatiaInstitute for Infection and Immunity, St George's, University of London, London, UK.
Emma Harding-EschInstitute for Infection and Immunity, St George's, University of London, London, UK Department of STI/HIV, Public Health England, Colindale, London, UK.
Irene M MonahanInstitute for Infection and Immunity, St George's, University of London, London, UK.
Timothy PlancheInstitute for Infection and Immunity, St George's, University of London, London, UK Medical Microbiology, South West London Pathology, St George's University Hospitals NHS Foundation Trust, London, UK.
Jason HindsInstitute for Infection and Immunity, St George's, University of London, London, UK.
Catherine A IsonSexually Transmitted Bacteria Reference Unit, Public Health England, Colindale, London, UK.
Stephanie ChisholmSexually Transmitted Bacteria Reference Unit, Public Health England, Colindale, London, UK.
Philip D ButcherInstitute for Infection and Immunity, St George's, University of London, London, UK.
Syed Tariq SadiqInstitute for Infection and Immunity, St George's, University of London, London, UK Department of Genitourinary & HIV Medicine, St George's University Hospitals NHS Foundation Trust, London, UK Department of STI/HIV, Public Health England, Colindale, London, UK ssadiq@sgul.ac.uk.
St George's, University of London · GBPublic Health England · GB

Funding

Medical Research Council G0901608
6 · The paper itself

Abstract

introductionIncreasing use of nucleic acid amplification tests (NAATs) as the primary means of diagnosing gonococcal infection has resulted in diminished availability of Neisseria gonorrhoeae antimicrobial susceptibility data. We conducted a prospective diagnostic assessment of a real-time PCR assay (NGSNP) enabling direct detection of gonococcal ciprofloxacin susceptibility from a range of clinical sample types.

methodsNGSNP, designed to discriminate an SNP associated with ciprofloxacin resistance within the N. gonorrhoeae genome, was validated using a characterized panel of geographically diverse isolates (n = 90) and evaluated to predict ciprofloxacin susceptibility directly on N. gonorrhoeae-positive NAAT lysates derived from genital (n = 174) and non-genital (n = 116) samples (n = 290), from 222 culture-confirmed clinical episodes of gonococcal infection.

resultsNGSNP correctly genotyped all phenotypically susceptible (n = 49) and resistant (n = 41) panel isolates. Ciprofloxacin-resistant N. gonorrhoeae was responsible for infection in 29.7% (n = 66) of clinical episodes evaluated. Compared with phenotypic susceptibility testing, NGSNP demonstrated sensitivity and specificity of 95.8% (95% CI 91.5%-98.3%) and 100% (95% CI 94.7%-100%), respectively, for detecting ciprofloxacin-susceptible N. gonorrhoeae, with a positive predictive value of 100% (95% CI 97.7%-100%). Applied to urogenital (n = 164), rectal (n = 40) and pharyngeal samples alone (n = 30), positive predictive values were 100% (95% CI 96.8%-100%), 100% (95% CI 87.2%-100%) and 100% (95% CI 82.4%-100%), respectively.

conclusionsGenotypic prediction of N. gonorrhoeae ciprofloxacin susceptibility directly from clinical samples was highly accurate and, in the absence of culture, will facilitate use of tailored therapy for gonococcal infection, sparing use of current empirical treatment regimens and enhancing acquisition of susceptibility data for surveillance.

Indexed as

Anti-Bacterial AgentsCiprofloxacinDrug Resistance, BacterialFemaleGenitaliaGonorrheaHumansMaleMicrobial Sensitivity TestsNeisseria gonorrhoeaePrecision MedicineReal-Time Polymerase Chain ReactionReproducibility of ResultsAnti-Bacterial AgentsCiprofloxacin

Identifiers

PMID26817487
PMCPMC4790619
OpenAlexW2330118486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.